Photodynamic targeting of human retinoblastoma cells using covalent low-density lipoprotein conjugates

Schmidt-Erfurth, U.; Diddens, H.; Birngruber, Reginald; Hasan, Tayyaba

doi:10.1038/bjc.1997.9

Cited by 94 publications

(44 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…37 Retinoblastoma cells internalize verteporfin via the LDL receptor, and these cells accumulate more verteporfin than do normal cells, which makes them a specific target for PDT. 164,187 We could not find any clinical studies about the therapeutic effects of verteporfin in retinoblastoma patients.…”

Section: A C C E P T E D Accepted Manuscriptmentioning

confidence: 92%

Clinical use of photodynamic therapy in ocular tumors

Çerman

Çekıç

2015

Survey of Ophthalmology

View full text Add to dashboard Cite

Section: A C C E P T E D Accepted Manuscriptmentioning

confidence: 92%

Clinical use of photodynamic therapy in ocular tumors

Çerman

Çekıç

2015

Survey of Ophthalmology

View full text Add to dashboard Cite

“…The endothelial cells in the CNV, which have an increased expression of low-density lipoprotein receptors, take up verteporfin [39]. PDT destroys verteporfin-laden endothelial cells in the CNV by oxidative stress [40].…”

Section: Discussionmentioning

confidence: 99%

Protective Effect of Intravitreal Bevacizumab and Sub-Tenon Triamcinolone Acetonide against Occlusion of Choriocapillaris Induced by Photodynamic Therapy

Mukai

Kishi²,

Sato³

et al. 2010

Ophthalmologica

View full text Add to dashboard Cite

Purpose: To evaluate the protective effect of intravitreal bevacizumab (IVB) and sub-Tenon triamcinolone acetonide (TA) against choriocapillaris occlusion induced by photodynamic therapy (PDT). Methods: This prospective, nonrandomized, consecutive study included 80 eyes of 80 patients with polypoidal choroidal vasculopathy who underwent an initial PDT. The posttherapeutic follow-up periods were more than 3 months (mean, 9.3 months). Patients were divided into three groups consecutively: the PDT group included 21 eyes of 21 patients treated with only PDT, the TA group included 32 eyes of 32 patients treated with PDT and a sub-Tenon injection of 20 mg TA, and the IVB group included 27 eyes of 27 patients treated with PDT and an intravitreal injection of 1.25 mg bevacizumab. Indocyanine green angiography (ICGA) was performed before and 3 months after PDT. The degree of choriocapillaris occlusion was assessed in the marginal zone of the PDT area based on the background hypofluorescence seen on ICGA quantified by densitometry (Imagenet). Results: ICGA at 1 and 5 min showed hypofluorescence in the marginal zone in all eyes 3 months after PDT. The hypofluorescence became indistinguishable from the background fluorescence 15 min after treatment in some eyes; however, the relative hypofluorescence persisted in some cases. The rates of fluorescence intensity in the marginal zone compared to those in the untreated area, i.e. the percentage of baseline fluorescence, were 0.60, 0.65 and 0.73 at 1, 5 and 15 min after dye injection in the PDT group, respectively, 0.64, 0.68 and 0.82 in the TA group, and 0.64, 0.73 and 0.90 in the IVB group. The intensity of the fluorescence was significantly (p < 0.05) higher in the TA group at 15 min and in the IVB group at 1, 5 and 15 min compared with the PDT group. Conclusions: IVB and TA reduced choriocapillaris occlusion after PDT. IVB appeared to have a stronger protective effect than TA in this therapeutic regimen.

show abstract

“…In an attempt to overcome this research in PDT in oncology has focused on developing PS's conjugated to tumour targeted biological molecules [28]. Porphyrins have been successfully conjugated to a vari-ety of biomolecules including mAbs [26,41,42], lipoproteins [43,44] and nanoparticles [45] which allowed for more targeted delivery of PS, and therefore a more specific tissue response with limited damage to nor-mal tissue. A number of porphyrins have been developed that conjugate to biomolecules under mild conditions through direct reaction with lysine residues [26,33,46].…”

Section: Introductionmentioning

confidence: 99%

Duramycin-porphyrin conjugates for targeting of tumour cells using photodynamic therapy

Broughton

Giuntini

Savoie

et al. 2016

Journal of Photochemistry and Photobiology B: Biology

View full text Add to dashboard Cite

show abstract

Photodynamic targeting of human retinoblastoma cells using covalent low-density lipoprotein conjugates

Abstract: Summary Combination of photosensitizers with carrier molecules has been shown to enhance the efficiency of photodynamic therapy (PDT

Cited by 94 publications

References 46 publications

Clinical use of photodynamic therapy in ocular tumors

Clinical use of photodynamic therapy in ocular tumors

Protective Effect of Intravitreal Bevacizumab and Sub-Tenon Triamcinolone Acetonide against Occlusion of Choriocapillaris Induced by Photodynamic Therapy

Duramycin-porphyrin conjugates for targeting of tumour cells using photodynamic therapy

Contact Info

Product

Resources

About